RT Journal Article
SR Electronic
T1 Genome-to-genome analysis reveals associations between human and mycobacterial genetic variation in tuberculosis patients from Tanzania
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.11.23289848
DO 10.1101/2023.05.11.23289848
A1 Xu, Zhi Ming
A1 Zwyer, Michaela
A1 Brites, Daniela
A1 Hiza, Hellen
A1 Sasamalo, Mohamed
A1 Reinhard, Miriam
A1 Doetsch, Anna
A1 Borrell, Sonia
A1 Naret, Olivier
A1 Rüeger, Sina
A1 Lawless, Dylan
A1 Isihaka, Faima
A1 Temba, Hosiana
A1 Maroa, Thomas
A1 Naftari, Rastard
A1 Beisel, Christian
A1 Hella, Jerry
A1 Reither, Klaus
A1 Portevin, Damien
A1 Gagneux, Sebastien
A1 Fellay, Jacques
YR 2023
UL http://medrxiv.org/content/early/2023/05/11/2023.05.11.23289848.abstract
AB The risk and prognosis of tuberculosis (TB) are affected by both human and bacterial genetic factors. To identify interacting human and bacterial genetic loci, we leveraged paired human and Mycobacterium tuberculosis (M.tb) genomic data from 1000 Tanzanian TB patients. Through a genome-to-genome approach, we identified two pairs of human and M.tb genetic variants that are significantly associated. One of the human genetic variants maps to the intron of PRDM15, a gene involved in apoptosis regulation. The other human variant maps to an intergenic region close to TIMM21 and FBXO15. In addition, we observed that a group of linked M.tb epitope variants were significantly associated with HLA-DRB1 variation. This suggests that even though epitope variation is rare in M.tb in general, specific epitopes might still be under immune selective pressure. Overall, our study pinpoints sites of genomic conflicts between humans and M.tb, suggesting bacterial escape from host selection pressure.Competing Interest StatementO.N. is now an employee of SUN bioscience SA. S.R. is now an employee of Novartis AG.Funding StatementThis work was supported by the Swiss National Science Foundation (Grants: CRSII5-177163 and 310030-188888) and the European Research Council (Grant: 883582).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the TB-DAR cohort has been obtained from the Ethikkomission Nordwest- und Zentralschweiz (EKNZ UBE-15/42), the Ifakara Health Institute-Institutional Review Board Board (IHI/IRB/EXT/No: 24-2020) and the National Institute for Medical Research in Tanzania-Medical Research Coordinating Committee (NIMR/HQ/R.8c/Vol.I/1622). A written informed consent has been obtained from every patient who has been recruited into the TB-DAR cohort.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe bacterial WGS data has been published under bioproject PRJEB49562. Human genotyping and WGS data are deposited on the European Genome-phenome Archive (EGA) under EGAS00001007216 and EGAS00001005850 respectively.